Immunitybio Inc (IBRX)

$7.79 -0.43 (-5.23%)
Market Cap 8.61B
Revenue (ttm) 113.29M
Net Income (ttm) -351.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.18%
Debt to Equity Ratio 0.00
Volume 9,887,500
Avg Vol 13,644,786
Day's Range N/A - N/A
Shares Out 1.05B
Stochastic %K 3%
Beta 0.01
Analysts Strong Sell
Price Target $12.06

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
SlaveLifeAllLife
SlaveLifeAllLife Jul. 14 at 4:01 PM
$IBRX Multiple sources say $30B is big, but not as big as $50B
0 · Reply
TheWinningStock
TheWinningStock Jul. 14 at 3:59 PM
$CRDL <<---it will get approval. $IBRX $PFE <<--will have their day in the market fairly soon..
0 · Reply
SlaveLifeAllLife
SlaveLifeAllLife Jul. 14 at 3:58 PM
$IBRX Anyone can write some posts on the internet. "Multiple sources say, PSS will make everyone with 100 shares of IBRX rich this month."
0 · Reply
Larry5500
Larry5500 Jul. 14 at 3:56 PM
$IBRX very
0 · Reply
chartsbyTerrio
chartsbyTerrio Jul. 14 at 3:54 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $ONDS $SOFI $IBRX $BB on a different level
0 · Reply
kcajsnikrep
kcajsnikrep Jul. 14 at 3:48 PM
$IBRX I refuse to get excited
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Jul. 14 at 3:43 PM
$IBRX any of us can start a rumor ! I’ll one up the guy ! Ibrx will be approved for all cancers as soon as my boy Trump bombs the hell out of Iran into submission !
1 · Reply
PastaSlobCFA
PastaSlobCFA Jul. 14 at 3:41 PM
$IBRX big momma short squeeze about to come in after the 12:00 press release!!!!
1 · Reply
PumpXXX
PumpXXX Jul. 14 at 3:40 PM
$IBRX wondering what those multiple sources are? Just some guys on Social Media like you and me? I mean, i am bullish af but to be honest this is just not valid, isnt it?
1 · Reply
DannyMac56
DannyMac56 Jul. 14 at 3:36 PM
$IBRX Who is going to score a goal today.....I mean, which team wins in a "thriller?" France or Spain?
2 · Reply
Latest News on IBRX
ImmunityBio Transcript: AGM 2026

Jun 9, 2026, 1:30 PM EDT - 4 weeks ago

ImmunityBio Transcript: AGM 2026

ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 5 weeks ago

ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Jun 1, 2026, 1:51 PM EDT - 6 weeks ago

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

May 25, 2026, 11:05 AM EDT - 7 weeks ago

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

May 22, 2026, 3:08 PM EDT - 7 weeks ago

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

DEADLINE NEXT WEEK: Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors to Contact the Firm Before May 26, 2026

May 22, 2026, 8:41 AM EDT - 7 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors to Contact the Firm Before May 26, 2026

ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026

2026-05-22T11:52:03.000Z - 7 weeks ago

ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026

ImmunityBio presents health economic analysis on ANKTIVA plus BCG

2026-05-22T11:49:46.000Z - 7 weeks ago

ImmunityBio presents health economic analysis on ANKTIVA plus BCG

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026, 7:30 AM EDT - 7 weeks ago

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA

2026-05-20T01:35:07.000Z - 7 weeks ago

ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

May 19, 2026, 8:30 PM EDT - 7 weeks ago

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

ImmunityBio announces results from ITC analyses of NAI with BCG

2026-05-19T11:42:41.000Z - 2 months ago

ImmunityBio announces results from ITC analyses of NAI with BCG

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

ImmunityBio announces five U.S. patents issued for Anktiva with BCG

2026-05-18T11:48:56.000Z - 2 months ago

ImmunityBio announces five U.S. patents issued for Anktiva with BCG

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

May 18, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory

2026-05-17T15:45:06.000Z - 2 months ago

ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

May 16, 2026, 1:35 PM EDT - 2 months ago

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

May 15, 2026, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

INKT

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

May 14, 2026, 8:30 AM EDT - 2 months ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GTBP

ImmunityBio price target lowered to $12 from $13 at BTIG

2026-05-08T12:57:59.000Z - 2 months ago

ImmunityBio price target lowered to $12 from $13 at BTIG

ImmunityBio reports Q1 EPS (62c) vs (15c) last year

2026-05-07T14:33:22.000Z - 2 months ago

ImmunityBio reports Q1 EPS (62c) vs (15c) last year

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

May 7, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

ImmunityBio Earnings release: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio Earnings release: Q1 2026

ImmunityBio Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio Quarterly report: Q1 2026

ImmunityBio presents new comparison results on Anktiva, TAR-200

2026-05-05T11:51:28.000Z - 2 months ago

ImmunityBio presents new comparison results on Anktiva, TAR-200

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

May 5, 2026, 7:30 AM EDT - 2 months ago

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

Apr 30, 2026, 9:00 AM EDT - 2 months ago

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

ImmunityBio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

ImmunityBio Proxy statement: Proxy filing

ImmunityBio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

ImmunityBio Proxy statement: Proxy filing

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt

Apr 23, 2026, 9:00 AM EDT - 2 months ago

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

Apr 21, 2026, 11:21 AM EDT - 3 months ago

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

2026-04-21T11:56:04.000Z - 3 months ago

ImmunityBio announces availability of ANKTIVA in Saudi Arabia

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

Apr 21, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 20, 2026, 4:29 PM EDT - 3 months ago

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

Apr 16, 2026, 9:00 AM EDT - 3 months ago

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

Apr 15, 2026, 8:00 PM EDT - 3 months ago

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 15, 2026, 9:36 AM EDT - 3 months ago

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

ImmunityBio reports preliminary Q1 net product revenue $44.2M

2026-04-09T12:01:21.000Z - 3 months ago

ImmunityBio reports preliminary Q1 net product revenue $44.2M

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

Apr 9, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

Apr 8, 2026, 6:00 PM EDT - 3 months ago

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance

2026-04-06T11:36:39.000Z - 3 months ago

ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Apr 6, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

ImmunityBio announces $100M of financing transactions

2026-03-31T11:43:01.000Z - 3 months ago

ImmunityBio announces $100M of financing transactions

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Mar 31, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

ImmunityBio announces IDMC says QUILT-2.005 adequately powered

2026-03-26T11:36:38.000Z - 3 months ago

ImmunityBio announces IDMC says QUILT-2.005 adequately powered

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Mar 26, 2026, 7:30 AM EDT - 3 months ago

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

ImmunityBio stock price crash: buy the dip or sell the rip?

Mar 24, 2026, 3:25 PM EDT - 3 months ago

ImmunityBio stock price crash: buy the dip or sell the rip?

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 12:56 PM EDT - 3 months ago

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SlaveLifeAllLife
SlaveLifeAllLife Jul. 14 at 4:01 PM
$IBRX Multiple sources say $30B is big, but not as big as $50B
0 · Reply
TheWinningStock
TheWinningStock Jul. 14 at 3:59 PM
$CRDL <<---it will get approval. $IBRX $PFE <<--will have their day in the market fairly soon..
0 · Reply
SlaveLifeAllLife
SlaveLifeAllLife Jul. 14 at 3:58 PM
$IBRX Anyone can write some posts on the internet. "Multiple sources say, PSS will make everyone with 100 shares of IBRX rich this month."
0 · Reply
Larry5500
Larry5500 Jul. 14 at 3:56 PM
$IBRX very
0 · Reply
chartsbyTerrio
chartsbyTerrio Jul. 14 at 3:54 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $ONDS $SOFI $IBRX $BB on a different level
0 · Reply
kcajsnikrep
kcajsnikrep Jul. 14 at 3:48 PM
$IBRX I refuse to get excited
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Jul. 14 at 3:43 PM
$IBRX any of us can start a rumor ! I’ll one up the guy ! Ibrx will be approved for all cancers as soon as my boy Trump bombs the hell out of Iran into submission !
1 · Reply
PastaSlobCFA
PastaSlobCFA Jul. 14 at 3:41 PM
$IBRX big momma short squeeze about to come in after the 12:00 press release!!!!
1 · Reply
PumpXXX
PumpXXX Jul. 14 at 3:40 PM
$IBRX wondering what those multiple sources are? Just some guys on Social Media like you and me? I mean, i am bullish af but to be honest this is just not valid, isnt it?
1 · Reply
DannyMac56
DannyMac56 Jul. 14 at 3:36 PM
$IBRX Who is going to score a goal today.....I mean, which team wins in a "thriller?" France or Spain?
2 · Reply
mcstoxdox
mcstoxdox Jul. 14 at 3:29 PM
$IBRX i hope not
4 · Reply
MMoe1010
MMoe1010 Jul. 14 at 3:27 PM
$IBRX
0 · Reply
MMoe1010
MMoe1010 Jul. 14 at 3:23 PM
$IBRX
0 · Reply
Daredevilmillion
Daredevilmillion Jul. 14 at 3:21 PM
$IBRX numbers are good
0 · Reply
Eureka2005
Eureka2005 Jul. 14 at 3:20 PM
$IBRX Nothing to be worried, the earnings report, a big announcement and all the catalysts on their way. Buy and hold!
0 · Reply
HuskyNil
HuskyNil Jul. 14 at 3:20 PM
$IBRX Let’s Go!!
2 · Reply
Someday1
Someday1 Jul. 14 at 3:20 PM
$IBRX Institutional buying is going crazy.
0 · Reply
LB19
LB19 Jul. 14 at 3:13 PM
$IBRX Dr. Patrick is too quiet. I watched this man pump up Saudi trips, being called by health ministers by multiple countries, Leonardo manufacturing delivery etc. For him to be this quiet at this stage, something big time must be dropping soon.
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 14 at 3:12 PM
$IBRX New member just joined the club> nice BUY!
0 · Reply
fibonacci1170
fibonacci1170 Jul. 14 at 3:12 PM
$IBRX it's 14 July. Something gotta give in the next 17 days. I reckon Leonardo delivery to Saudi Arabia or anktiva label expansion by Saudi Arabia. Whatever it is, will likely increase the upside to a value that we have not thought of.
1 · Reply
jut1
jut1 Jul. 14 at 3:11 PM
$IBRX Any updates from the company on positive glioblastoma Trials? People could really use it https://www.dailyherald.com/20260714/celebrities/antiques-roadshow-star-theo-burrell-dies-of-glioblastoma-at-39/
1 · Reply
Daredevilmillion
Daredevilmillion Jul. 14 at 3:09 PM
$IBRX Q2 surpassed $54 million
0 · Reply